Enable JavaScript to visit this website.

Why Celebrex

All fields are required.

Privacy Statement

Privacy is important to us. To learn more about our use of your information and your rights, please consult our Privacy Policy.

For 20 years, brand-name CELEBREX has been prescribed to more than 35 million patients. If you have osteoarthritis or rheumatoid arthritis pain, ask your doctor about moving forward with brand-name CELEBREX—only from Pfizer.

Celebrex is clinically proven

  • Osteoarthritis:

    CELEBREX is proven to significantly reduce joint pain compared to sugar pill*

  • Rheumatoid arthritis:

    CELEBREX demonstrated significant reduction in joint tenderness/pain and joint swelling compared to sugar pill*

  • Acute pain:

    Single doses of CELEBREX provided relief within 60 minutes

Effectiveness of CELEBREX was shown to be similar to that of naproxen 500 mg twice daily.

Individual results may vary.

CARDIOVASCULAR SAFETY STUDY

CELEBREX PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE TAKING CELEBREX 100 MG TWICE A DAY

  • Did not show an increased risk of having a stroke, heart attack, or dying from a cardiovascular cause compared with patients taking ibuprofen 600-800 mg (three times a day) or naproxen 375-500 mg (twice daily)
  • Did not have worsening blood pressure when compared with patients who took ibuprofen 600-800 mg (three times a day)§

This is statistically significant.

§Comparison not statistically significant. This was a sub-study of 444 patients at 4 months.

Celebrex is the brand you recognize

  • The CELEBREX pill has a distinctive shape and marking to let you know you're getting the brand-name medication—pill to pill, month to month

  • Brand-name CELEBREX is from a company you know—only from Pfizer

  • You have the assurance that Pfizer stands behind its manufacturing standards

Celebrex Offers Savings To Patients

If eligible, patients may pay as little as $4 for each 30-day fill of brand-name CELEBREX—and could save up to $1,750 a year.*

Bottom text: 

This was a double-blind, triple-dummy, multicenter, parallel group, non-inferiority CV safety study in OA and RA patients with or at high risk of cardiovascular disease comparing celecoxib with ibuprofen or naproxen.

X

You Are Leaving Celebrex.com

Links to another site are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

X

You Are Leaving Celebrex.com

The information provided in CELEBREXHCP.com is intended only for healthcare professionals in the United States.